Tá Mirvetuximab soravtansine-gynx ceadaithe ag an USFDA le haghaidh ubhagán epithelial FRα dearfach, platanam-resistant, feadán fallopian, nó ailse peritoneal bunscoile
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, platinum-resistant epithelial ..
Trialacha cliniciúla
Teiripe Cealla MESO-CAR T le haghaidh Ailse Ubhagán Epithelial Athiompaithe agus Teasfhulangacha
March 2023: Brief Summary: The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has come back or stopped responding to other..
mirvetuximab soravtansine-gyn
Tugtar faomhadh luathaithe do Mirvetuximab soravtansine-gynx le haghaidh ubhagán epithelial FRα dearfach, platanam-resistant, feadán fallopian, nó ailse peritoneal
Samhain 2022: I gcás othair aosach a raibh ceann amháin nó trí réimeas cóireála sistéamach acu roimhe seo agus a bhfuil ubhagán epithelial deimhneach, ovarian platanam-resistant, feadán fallopian, nó ailse peritoneal príomhúil acu, is féidir an F..
Lancet, Meicinist, Tamoxifen, Trametinib
Cóireáil nua sainaitheanta le haghaidh ailse ubhagán ghrád íseal agus thromchúiseach
May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy an..
Cytalux, NCT03180307, pafolacianine, Target Laboratories
Tá Pafolacianine ceadaithe chun loit ailse ovártha urchóideacha a aithint
Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, has been licenced by the Food and Drug Administration for adult patients with ovarian cancer as an adjuvant for interoperative detection of..
Niraparib
Baineann Niraparib torthaí iontacha amach le haghaidh ailse ubhagáin agus ailse chíche
Ailse chíche & ubhagáin Más othar ailse chíche agus ubhagáin tú, tarlaíonn sé go bhfaighidh tú gur ailse den sóchán BRCA1 / 2 tú tar éis duit an tástáil ghéiniteach a rith, agus go sábhálfar do shaol. De réir an Oncolog Domhanda ..
Acalabrutunib, Avelumab, Teiripe CART, Dabrafanib, Cimriah, Drugaí is déanaí, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Na drugaí is déanaí i gcóireáil ailse
Iúil 2021: Amharc ar na drugaí is déanaí maidir le cóireáil ailse. Gach bliain, tar éis na trialacha agus fachtóirí tábhachtacha eile a scrúdú, formheasann an USFDA drugaí, agus dá bhrí sin is féidir le hothair ailse a chreidiúint anois go bhfuil leigheas an-ghar. ..